Evidence map›Paper›PMID 42326541›Full record

ArticleCancer management and research2026

Berberine from Tibetan Medicine

Yating Wang, Yanning Zhang, Qiang Wang, Linfan Zheng, Yan Liu

Abstract read
In one paragraph

Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yating WangDepartment of Traditional Chinese Medicine, School of Medicine, Qinghai University, Xining, Qinghai, 810006, People's Republic of China.ORCID 0009-0001-5147-4180
Yanning ZhangDepartment of Traditional Chinese Medicine, School of Medicine, Qinghai University, Xining, Qinghai, 810006, People's Republic of China.ORCID 0009-0008-9013-9976
Qiang WangDepartment of Traditional Chinese Medicine, School of Medicine, Qinghai University, Xining, Qinghai, 810006, People's Republic of China.
Linfan ZhengDepartment of Traditional Chinese Medicine, School of Medicine, Qinghai University, Xining, Qinghai, 810006, People's Republic of China.
Yan LiuDepartment of Traditional Chinese Medicine, School of Medicine, Qinghai University, Xining, Qinghai, 810006, People's Republic of China.ORCID 0000-0001-8037-144X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to identify berberine as the candidate active constituent of Methods: The antitumor activity of Results: BBR, a putatively annotated candidate metabolite putatively annotated from DME, attenuated ferroptosis in tumor-infiltrating CD8⁺ T cells, as confirmed by rescue assays using ferroptosis inducers. Accordingly, BBR treatment increased the proportion of functional CD8⁺ T cells while reducing exhausted T-cell populations in both in vitro and in vivo models. Mechanistically, BBR activated the NRF2-SLC7A11-GPX4 axis, leading to GPX4 upregulation and ferroptosis suppression in CD8⁺ T cells. Conclusion: Berberine, a candidate metabolite derived from

Indexed as

berberineCD8+ T cellscolorectal cancerDracocephalum tanguticum Maximferroptosis

Identifiers

PMID42326541
PMCPMC13282992

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.